# Efficacy of Oral Acetazolamide in Decongestion in Patients With Heart Failure

Study · id `cardio:ct-nct05940220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05940220](<https://clinicaltrials.gov/study/NCT05940220>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05940220

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 130 participants.

## Technical summary

Registry record NCT05940220. Randomized; double masking; primary purpose treatment. Start 2023-12-30 (anticipated); primary completion 2025-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 130 participants (planned count; ClinicalTrials.gov record NCT05940220, source copy `cardio:ctgov-nct05940220-2023-08-01`, retrieved 2026-10-26)
- Planned start: 2023-12-30 (anticipated) (ClinicalTrials.gov record NCT05940220, source copy `cardio:ctgov-nct05940220-2023-08-01`, retrieved 2026-10-26)
- Primary completion: 2025-06-30 (anticipated) (ClinicalTrials.gov record NCT05940220, source copy `cardio:ctgov-nct05940220-2023-08-01`, retrieved 2026-10-26)
- Completion: 2025-10-10 (anticipated) (ClinicalTrials.gov record NCT05940220, source copy `cardio:ctgov-nct05940220-2023-08-01`, retrieved 2026-10-26)
- Countries: Iran (ClinicalTrials.gov record NCT05940220, source copy `cardio:ctgov-nct05940220-2023-08-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05940220-2023-08-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy of Oral Acetazolamide in Decongestion in Patients With Heart Failure
- Condition: Heart Failure
- Intervention (Other): Acetazolamide
- Intervention (Other): placebo
- Lead sponsor: Tehran University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Tehran University of Medical Sciences (`cardio:org-tehran-university-of-medical-sciences`)

## Provenance

Content hash: 62344495891ad8d6e9c49f3988d8f52c465734c49dc7e6ac19045f52752b385d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
